Salud
AstraZeneca’s lung cancer drug trial shows no significant improvement
Detailed results from one of AstraZeneca’s pivotal trials of a lung cancer drug, published on Monday, showed that the experimental precision drug had no significant
FDA lifts partial clinical hold on Rezolute hypoglycemia treatment
Resolute said the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage study testing its treatment for low blood sugar,
Biden administration finalizes rule to strengthen mental health parity law
The Biden administration said it had finalized a regulation to help ensure that the 175 million Americans with private health insurance have access to affordable
China plans to allow wholly foreign-owned hospitals
China said it will allow the establishment of wholly foreign-owned hospitals in nine areas of the country, including the capital. The new policy was a
Asthma drug meets main goal of study to treat smokers’ lungs
UK drugmaker GSK said its asthma drug Nucala has achieved the primary endpoint of a late-stage study in patients with chronic obstructive pulmonary disease, or
CDC confirms human case of bird flu in Missouri
The US Centres for Disease Control and Prevention on Friday confirmed a human case of avian influenza A reported in the state of Missouri. According
India reports a case of mpox in a traveller from an affected country
India has registered a suspected case of mpox in a man who recently travelled from a country where an outbreak of the virus has been
EU delivered first doses of mpox vaccine to Congo
The Democratic Republic of Congo received its first batch of 100,000 mpox vaccines from the European Union on Thursday, with a second delivery expected in
US authorises increased production of Takeda’s ADHD drug to address shortages
The US Drug Enforcement Administration has increased the production limit for Takeda Pharmaceuticals’ ADHD drug Vyvanse and its generics have increased in price by about
Johnson & Johnson adds $1.1 billion to proposed talcum powder settlement
Johnson & Johnson plans to pay an additional $1.1 billion to settle tens of thousands of lawsuits alleging that baby powder and other talc-based products